Federal regulators have approved a much broader use for Cubist Pharmaceuticals Inc.'s Cubicin intravenous antibiotic, which could mean millions of additional dollars in revenue down the line.

The Lexington, MA, company announced late Thursday the U.S. Food and Drug Administration approved expanding Cubicin's indication from skin infections to also treat bloodstream infections, including a form of endocarditis.

Cubist said it will begin marketing immediately.

Cubicin has been a major boon to Cubist. The drug reached $100 million in sales just seven months after its November 2003 launch. Expanding the drug's potential uses has been a major goal for Cubist. Last November, the company announced it would boost its hospital sales force from 99 to at least 135 in anticipation of the expanded regulatory approval.

Based on that news, the company has reaffirmed its net product revenue guidance for 2006 of between $190 million and $205 million.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP